D.E. Shaw & Co’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-10,811
| Closed | -$23.6K | – | 4537 |
|
|
2024
Q1 | $23.6K | Sell |
10,811
-766
| -7% | -$1.41K | ﹤0.01% | 4113 |
|
|
2023
Q4 | $17.9K | Sell |
11,577
-61,917
| -84% | -$81.4K | ﹤0.01% | 4076 |
|
|
2023
Q3 | $94.8K | Sell |
73,494
-56,966
| -44% | -$89.7K | ﹤0.01% | 3855 |
|
|
2023
Q2 | $224K | Sell |
130,460
-170,381
| -57% | -$283K | ﹤0.01% | 3708 |
|
|
2023
Q1 | $454K | Sell |
300,841
-317,533
| -51% | -$718K | ﹤0.01% | 3597 |
|
|
2022
Q4 | $989K | Buy |
618,374
+128,744
| +26% | +$190K | ﹤0.01% | 3460 |
|
|
2022
Q3 | $710K | Buy |
489,630
+242,153
| +98% | +$373K | ﹤0.01% | 3827 |
|
|
2022
Q2 | $453K | Buy |
247,477
+77,526
| +46% | +$148K | ﹤0.01% | 4146 |
|
|
2022
Q1 | $454K | Buy |
+169,951
| New | +$653K | ﹤0.01% | 4427 |
|
|
2021
Q4 | – | Sell |
-26,297
| Closed | -$134K | – | 5459 |
|
|
2021
Q3 | $134K | Sell |
26,297
-163,147
| -86% | -$873K | ﹤0.01% | 4663 |
|
|
2021
Q2 | $1.2M | Sell |
189,444
-129,037
| -41% | -$1M | ﹤0.01% | 3392 |
|
|
2021
Q1 | $2.46M | Sell |
318,481
-297,518
| -48% | -$2.35M | ﹤0.01% | 2420 |
|
|
2020
Q4 | $4.04M | Buy |
615,999
+103,511
| +20% | +$739K | ﹤0.01% | 2042 |
|
|
2020
Q3 | $3.41M | Buy |
512,488
+147,391
| +40% | +$1.09M | ﹤0.01% | 1975 |
|
|
2020
Q2 | $3.04M | Sell |
365,097
-157,555
| -30% | -$1.46M | ﹤0.01% | 2073 |
|
|
2020
Q1 | $4.01M | Sell |
522,652
-177,449
| -25% | -$1.24M | 0.01% | 1629 |
|
|
2019
Q4 | $5.82M | Buy |
700,101
+363,097
| +108% | +$2.45M | 0.01% | 1608 |
|
|
2019
Q3 | $2.49M | Buy |
337,004
+4,810
| +1% | +$47.4K | ﹤0.01% | 2200 |
|
|
2019
Q2 | $3.73M | Sell |
332,194
-47,560
| -13% | -$499K | ﹤0.01% | 1805 |
|
|
2019
Q1 | $4.08M | Buy |
379,754
+246,072
| +184% | +$3.64M | 0.01% | 1673 |
|
|
2018
Q4 | $2.02M | Buy |
133,682
+11,365
| +9% | +$169K | ﹤0.01% | 2139 |
|
|
2018
Q3 | $2.26M | Buy |
122,317
+14,264
| +13% | +$325K | ﹤0.01% | 2109 |
|
|
2018
Q2 | $2.47M | Buy |
108,053
+30,538
| +39% | +$780K | ﹤0.01% | 2067 |
|
|
2018
Q1 | $2.2M | Buy |
77,515
+47,034
| +154% | +$1.34M | ﹤0.01% | 1981 |
|
|
2017
Q4 | $643K | Buy |
30,481
+17,998
| +144% | +$373K | ﹤0.01% | 2833 |
|
|
2017
Q3 | $227K | Buy |
+12,483
| New | +$195K | ﹤0.01% | 3255 |
|
|
2016
Q1 | – | Sell |
-21,257
| Closed | -$444K | – | 3473 |
|
|
2015
Q4 | $444K | Buy |
+21,257
| New | +$336K | ﹤0.01% | 3149 |
|
Other funds holding CTMX
TCM
D.E. Shaw & Co's CTMX Position: Q2 2024 in Review
D.E. Shaw & Co sold out of CytomX Therapeutics (CTMX) in Q2 2024, closing a stake of 10,811 shares — an estimated $23.6K sold.
D.E. Shaw & Co first reported a position in CTMX in Q4 2015 and held it in 27 quarters. The position peaked at $5.82M in Q4 2019. 74 funds tracked by Wall St. Rank hold CTMX as of Q2 2024.
- D.E. Shaw & Co reported no remaining CytomX Therapeutics position as of Q2 2024 after selling out during the quarter.
- D.E. Shaw & Co sold 10,811 CytomX Therapeutics shares in Q2 2024, an estimated $23.6K.
- D.E. Shaw & Co first reported a position in CytomX Therapeutics in Q4 2015 and held it in 27 quarters.
- D.E. Shaw & Co's CytomX Therapeutics position peaked at $5.82M in Q4 2019.
- 74 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2024.
Based on D.E. Shaw & Co's 13F filing for Q2 2024, filed 14 Aug 2024.